Skip to main
INFU

InfuSystem Hlds (INFU) Stock Forecast & Price Target

InfuSystem Hlds (INFU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

InfuSystems Holdings is expected to see a decrease in annual revenue of $7.1M due to a restructured contract with their largest biomedical services customer. Despite this, pro forma revenue is expected to grow 6-8% and adjusted EBITDA margin is expected to improve thanks to planned reductions in expenses and increased efficiency benefits. The company's core oncology business is performing well, and they are investing in new growth drivers such as wound care and pain management. While regulatory setbacks and competition could potentially impede growth, the company's strong operating cash flow, repurchasing of stock, and strong liquidity give a positive outlook for its stock.

Bears say

InfuSystems Holdings is facing ongoing competitive pressures from larger players such as McKesson and Option Care Health. Additionally, the company's significant reliance on third-party payers for revenue raises vulnerability to potential changes in coverage policies and reimbursement rates, which could negatively impact margins. Furthermore, any delays in growth drivers such as Wound Care and Pain Management becoming material contributors could impede achieving the target price of $15.

InfuSystem Hlds (INFU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InfuSystem Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InfuSystem Hlds (INFU) Forecast

Analysts have given InfuSystem Hlds (INFU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, InfuSystem Hlds (INFU) has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InfuSystem Hlds (INFU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.